First Human Injection of Reverse-Aging Drug (Cellular Reprogramming)
Key Questions
What is the reverse-aging drug that was recently injected into a human?
The therapy uses cellular reprogramming to target aging at the cellular level and was first administered in a glaucoma clinical trial. It includes an on/off safety switch designed to reduce cancer risk associated with reprogramming techniques.
Why was the drug tested in a glaucoma trial rather than for systemic aging?
The initial trial focuses on glaucoma as a localized application to establish safety and efficacy in humans. Systemic aging implications are considered significant but remain early-stage and untested at this point.
What makes this injection a breakthrough in longevity science?
It marks the first time a cellular reprogramming treatment aimed at reversing aspects of aging has been used in a human patient. The on/off mechanism addresses key safety concerns while opening pathways for broader future applications.
A drug targeting cellular reprogramming has been injected into a human for the first time, in a glaucoma trial. The therapy includes an on/off safety switch to manage cancer risk. Implications for systemic aging are significant, though early-stage. Status: developing.